Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
DALLAS and FORT WORTH, Texas, Feb. 16, 2016 -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing and commercializing innovative extended-release (XR) products for the treatment of attention-deficit/hyperactivity disorder (ADHD), today announced that Vipin Garg, PhD, President and CEO, will present at the following investor conferences:
- 2016 RBC Capital Markets Healthcare Conference taking place in New York, February 23 - 24. The presentation is scheduled for Tuesday, February 23, at 3:05 p.m. ET.
- Cowen and Company 36th Annual Health Care Conference taking place in Boston, March 7 - 9. The presentation is scheduled for Tuesday, March 8, at 10:00 a.m. ET.
- BioCentury 23rd Annual Future Leaders in the Biotech Industry conference taking place in New York on March 11. Dr. Garg will present at 9:00 a.m. ET.
Live webcasts of these presentations will be available in the investor section of the company’s website, http://investors.neostx.com/ and will be archived on the website.
About Neos Therapeutics
Neos Therapeutics, Inc. is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified‐release drug delivery technology platforms. The Company recently received FDA approval of Adzenys XR-ODTTM - the first and only FDA-approved amphetamine extended-release orally disintegrating tablet for the treatment of ADHD. Neos has two other branded product candidates in development, an XR-ODT of methylphenidate and a liquid suspension of amphetamine for the treatment of ADHD. In addition, Neos manufactures and markets its generic equivalent of the branded product Tussionex®1, an XR liquid suspension of hydrocodone and chlorpheniramine indicated for the relief of cough and upper respiratory symptoms of a cold.
1Tussionex® is a registered trademark of the UCB Group of Companies
CONTACTS:
Richard I. Eisenstadt, Chief Financial Officer
Neos Therapeutics
(972) 408‐1389
[email protected]
David Carey, Investor Relations
Lazar Partners
(212) 867‐1768
[email protected]
